Who are Erenumab Auto-Injector's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ZAVEGEPANT, rimegepant 75 mg ODT, Placebo-Matching Atogepant, Placebo to telcagepant capsules, Placebo to telcagepant tablets, CGRP mAbs and onabotulinumtoxin A.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/erenumab-auto-injector.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Erenumab Auto-Injector — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Erenumab Auto-Injector (Erenumab Auto-Injector) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Neurology.

phase 2 monoclonal antibody CGRP receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Erenumab Auto-Injector (Erenumab Auto-Injector) — Clinique des Céphalées de Montréal. Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Erenumab Auto-Injector TARGET	Erenumab Auto-Injector	Clinique des Céphalées de Montréal	phase 2	monoclonal antibody	CGRP receptor
ZAVEGEPANT	ZAVEGEPANT		marketed		CGRP receptor	2023-01-01
rimegepant 75 mg ODT	rimegepant-75-mg-odt	Pfizer	marketed	CGRP receptor antagonist	CGRP receptors
Placebo-Matching Atogepant	Placebo-Matching Atogepant	AbbVie	phase 3	CGRP receptor antagonist	CGRP receptor (calcitonin gene-related peptide receptor)
Placebo to telcagepant capsules	Placebo to telcagepant capsules	Merck Sharp & Dohme LLC	phase 3	CGRP receptor antagonist	CGRP receptor (calcitonin gene-related peptide receptor)
Placebo to telcagepant tablets	Placebo to telcagepant tablets	Merck Sharp & Dohme LLC	phase 3	CGRP receptor antagonist	CGRP receptor
CGRP mAbs and onabotulinumtoxin A	CGRP mAbs and onabotulinumtoxin A	Oslo University Hospital	phase 3	Monoclonal antibody + neurotoxin combination	CGRP/CGRP receptor and acetylcholine (via SNARE complex inhibition)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody class)

Pfizer · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Celltrion · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Clinique des Céphalées de Montréal · 1 drug in this class
Dermira, Inc. · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Gliknik Inc. · 1 drug in this class
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erenumab Auto-Injector — Competitive Intelligence Brief. https://druglandscape.com/ci/erenumab-auto-injector. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab